ClinicalTrials.gg
Enrolling by invitationNCT07567989Updated Nov 18, 2026

Effectiveness of Home-Based Exercise and Brain Stimulation for Reducing Fatigue in Patients With Multiple Sclerosis

An interventional study of Home-Based Therapeutic Exercise Program and Transcranial Direct Current Stimulation in Multiple Sclerosis, sponsored by Jacobo Formigo. Enrolling by invitation at 3 sites in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Jacobo Formigo · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jan 2025, registered Dec 2025).
Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 230 studies in Multiple Sclerosis with a site in Spain — 35 open to participants now, 56 under way, 14 of them phase 3. Multiple Sclerosis · Spain.

Planned enrollment
131st of 202
60 · median 137
Started
2025
with 24 others
No phase
68 of 230
22 open now
Primary completion
2027-02
later than 31 of 55 live
Registered
217th of 230
by date

Among the 230 studies in Multiple Sclerosis with a site in Spain, this one is the 131st largest by planned enrollment of the 202 interventional ones that give a count, is one of 25 that started in 2025, is one of 68 with no phase, reaches primary completion later than 31 of the 55 other live ones, and was the 217th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

35 of the 230 studies in Multiple Sclerosis with a site in Spain are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Multiple Sclerosis with a site in Spain, or all of them as a file.
02

Study summary

This randomized, double-blind, parallel-group clinical trial aims to assess the effectiveness of a combined intervention consisting of a home-based therapeutic exercise program and transcranial direct current stimulation (tDCS) for the management of fatigue in patients with multiple sclerosis (MS). Fatigue is one of the most disabling and prevalent symptoms in MS, significantly impacting patients' quality of life and functional independence.

Participants diagnosed with MS who meet inclusion criteria will be randomized into two groups:

Group 1: Home-based therapeutic exercise plus sham (placebo) tDCS

Group 2: Home-based therapeutic exercise plus active tDCS

The intervention will span a defined period, with tDCS sessions applied over the dorsolateral prefrontal cortex (DLPFC) using a standard montage and parameters validated in previous studies. The sham stimulation group will follow identical procedures without active current delivery, preserving blinding for participants and evaluators.

The therapeutic exercise program is designed to be feasible for home implementation, targeting key domains affected in MS such as strength, endurance, balance, and mobility. Exercises will be prescribed based on individual patient assessments and progressively adjusted throughout the intervention period.

Primary outcome measures will include functional capacity, evaluated through the Six-Minute Walk Test (6MWT), and fatigue levels, assessed via the Fatigue Severity Scale (FSS) and a Visual Analogue Scale (VAS) for fatigue. Secondary observations may include adherence rates to the exercise program and subjective reports of tolerability and perceived benefits.

This trial seeks to explore whether combining a physical intervention (exercise) with a neuromodulation technique (tDCS) can offer additive benefits in managing fatigue, beyond what exercise alone provides. The ultimate goal is to develop accessible, non-pharmacological treatment strategies to improve daily functioning and quality of life for individuals living with multiple sclerosis.

Read the detailed description

This study is a randomized, double-blind, controlled clinical trial designed to investigate the efficacy of a combined intervention consisting of a structured home-based therapeutic exercise program and transcranial direct current stimulation (tDCS) for the treatment of fatigue in patients with multiple sclerosis (MS).

Eligible participants will be randomly assigned to one of two parallel groups:

An intervention group receiving a prescribed home-based exercise program in combination with active tDCS.

A control group receiving the same exercise program combined with sham (placebo) tDCS.

The tDCS intervention will target the dorsolateral prefrontal cortex (DLPFC) using a standardized electrode placement, with stimulation parameters based on protocols previously demonstrated to be safe and potentially effective in neurological populations. The sham condition will simulate the sensation of stimulation without delivering an active current, ensuring the integrity of the blinding process for both participants and evaluators.

The therapeutic exercise program will focus on improving muscular strength, cardiovascular endurance, balance, and functional mobility, components known to be affected in individuals with MS. The program will be tailored to individual baseline capabilities and progressively adapted throughout the intervention period to optimize participant engagement and safety.

Primary outcome measures include changes in functional exercise capacity, as assessed by the Six-Minute Walk Test (6MWT), and fatigue severity, evaluated using the Fatigue Severity Scale (FSS) and a Visual Analogue Scale (VAS) for fatigue. Adherence to the intervention and tolerability will also be monitored.

The proposed study addresses a critical need for accessible, non-pharmacological interventions to manage fatigue, one of the most common and disabling symptoms in MS. By combining physical rehabilitation strategies with neuromodulation techniques, the trial aims to determine whether synergistic effects can be achieved, potentially informing future clinical practices aimed at enhancing the quality of life of individuals with multiple sclerosis.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • Multiple Sclerosis
  • Fatigue
  • Home-Based exercise
  • tDCS
  • Transcranial Direct Current Stimulation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written
  • Confirmed diagnosis of multiple sclerosis
  • Presence of fatigue associated with multiple sclerosis, defined as a fatigue Visual Analogue Scale (VAS) score equal to or greater than 4
  • Functional capacity sufficient to perform the Six-Minute Walk Test (6MWT), assessed by a Functional Ambulation Category (FAC) score of 3 or higher

Exclusion criteria

Exclusion Criteria:

  • Presence of any neurological, rheumatological, or other medical condition prior to the diagnosis of multiple sclerosis that could interfere with the study outcomes
  • Presence of for transcranial direct current stimulation (tDCS), such as having a pacemaker, a history of epillepsy, pregnancy, implanted intracranial electrodes, defibrillator, or similar electronic devices.
  • Cognitive impairment that limits the participant's ability to collaborate with study procedures.
  • Any changes in physical therapy or pharmacological treatments for multiple sclerosis and/or fatigue that are not specified by the study protocol.
  • Occurrence of a multiple sclerosis relapse or disease progression with functional repercussions during the study period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Exercise Plus Active tDCS

    Participants assigned to this arm will complete a home-based therapeutic exercise program combined with active transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex (DLPFC). Stimulation parameters will follow validated protocols. Participants and outcomes assessors will be blinded to the assignment.

    Behavioral: Home-Based Therapeutic Exercise Program · Device: Transcranial Direct Current Stimulation

  • Placebo comparator
    Exercise Plus Sham tDCS

    Participants assigned to this arm will complete a home-based therapeutic exercise program combined with sham transcranial direct current stimulation (tDCS). Sham stimulation will mimic the sensation of tDCS without delivering an active current. Participants and outcomes assessors will be blinded to the assignment.

    Behavioral: Home-Based Therapeutic Exercise Program · Device: Sham tDCS

Interventions

  • BehavioralHome-Based Therapeutic Exercise Program

    Participants will engage in a structured home-based therapeutic exercise program administered via a smartphone application. The program consists of targeted strength training, stretching routines, and proprioceptive exercises designed to address functional impairments commonly observed in individuals with multiple sclerosis. Each session will have an approximate duration of 20 to 30 minutes. Participants are required to complete a minimum of three sessions per week for the duration of the intervention phase.

  • DeviceTranscranial Direct Current Stimulation

    Transcranial direct current stimulation (tDCS) targeting the left dorsolateral prefrontal cortex (DLPFC). Stimulation will be delivered using a standard electrode montage, with the anode positioned over the left DLPFC and the cathode over the contralateral supraorbital area. The stimulation parameters will include a current intensity of 1.5 mA applied for 20 minutes per session, with a ramp-up and ramp-down phase of 10 seconds each at the beginning and end of stimulation, respectively. Sessions will be conducted five days per week over a two-week period, for a total of 10 sessions.

    Also known as: tDCS

  • DeviceSham tDCS

    Participants assigned to the sham tDCS condition will receive identical electrode placement to the active tDCS group, with the anode over the left dorsolateral prefrontal cortex (DLPFC) and the cathode over the contralateral supraorbital area. The stimulation device will deliver an initial ramp-up phase of 10 seconds of actual stimulation after which no current will be delivered for 1180 seconds, and ending by a ramp-down phase of 10 seconds, The total session duration will match that of the active group (20 minutes), ensuring participant blinding. Sessions will occur five days per week over a two-week period, for a total of 10 sessions.

    Also known as: Sham Transcranial Direct Current Stimulation

06

What researchers measure

Primary outcomes

  1. Change in Fatigue Severity Measured by the Fatigue Severity Scale (FSS)

    Fatigue severity will be assessed using the Fatigue Severity Scale (FSS). The primary endpoint is the percentage reduction in the FSS total score compared to baseline. A clinically meaningful improvement is defined as a reduction greater than 20% in the FSS total score (approximately 13 points). Fatigue assessments will be conducted at baseline (prior to the intervention), at 10 days after the final tDCS session, at 3 months, and at 6 months post-intervention to evaluate both immediate and sustained effects.

    Time frame: Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline

  2. Change in Fatigue Severity Measured by Visual Analogue Scale (VAS) for Fatigue

    Fatigue severity will be assessed using a Visual Analogue Scale (VAS) for fatigue. The primary endpoint is the change in VAS fatigue score compared to baseline. A clinically meaningful improvement is defined as a reduction of at least 2 points on the VAS. Fatigue assessments will be conducted at baseline (prior to the intervention), at 10 days after the final tDCS session, at 3 months, and at 6 months post-intervention to evaluate both immediate and sustained effect

    Time frame: Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline

Secondary outcomes

  1. Change in Functional Capacity Measured by the Six-Minute Walk Test (6MWT)

    The Six-Minute Walk Test (6MWT) will be used to assess participants' functional exercise capacity by recording the total distance walked in six minutes. This test reflects submaximal functional endurance and mobility. Changes in distance walked will be compared to baseline measurements to evaluate improvements.

    Time frame: Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline

Other outcomes

  1. Change in Handgrip Strength Measured by Hand Dynamometry

    Handgrip strength will be measured using a standardized hand dynamometer (Jamar device). The maximal grip strength will be recorded in kilograms with one decimal place of precision. The values obtained will be compared with baseline measurements to assess changes in upper limb strength following the intervention.

    Time frame: Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline

  2. Change in Quality of Life Measured by EuroQol 5D (EQ-5D)

    Participants' self-perceived health status and quality of life will be evaluated using the EuroQol 5D questionnaire (EQ-5D). Changes from baseline in the EQ-5D score will be analyzed to determine whether the intervention has an impact on the participant's perception of overall health and quality of life.

    Time frame: Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline

  3. Change in Exercise Tolerance Measured by Distance Walked in the 6-Minute Walk Test (6MWT)

    Exercise tolerance will be assessed using the 6-Minute Walk Test (6MWT). The total distance walked (in meters) during the test will be recorded. Changes from baseline in the distance walked will be analyzed to evaluate the effect of the intervention on exercise tolerance.

    Time frame: Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline

  4. Change in Perceived Exertion After 6-Minute Walk Test Measured by Borg Rating of Perceived Exertion (RPE) Scale

    Participants' perception of exertion after the 6-Minute Walk Test (6MWT) will be assessed using the Borg Rating of Perceived Exertion (RPE) Scale (0-10). Changes from baseline in Borg RPE scores will be analyzed to evaluate the effect of the intervention on perceived exertion during exercise.

    Time frame: Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline

  5. Tolerance to tDCS Measured by Visual Analogue Scale (VAS)

    Tolerance to tDCS will be evaluated through a specific VAS (0 to 10)

    Time frame: Immediately after each stimulation session

  6. Adverse Events Associated With tDCS Application

    The frequency, intensity, and duration of adverse events related to tDCS (e.g., itching, tingling, headache) will be monitored through structured questionnaires completed after each session.

    Time frame: Throughout the Intervention Period (during each session)

  7. Change in Self-Perceived Health Status Measured by EuroQol Visual Analogue Scale (EQ-VAS, EuroQol Thermometer)

    Participants' self-perceived health status will be evaluated using the EuroQol Visual Analogue Scale (EQ-VAS, EuroQol Thermometer), a visual analogue scale ranging from 0 to 100. Changes from baseline in the EQ-VAS score will be analyzed to determine whether the intervention has an impact on the participant's perception of overall health statu

    Time frame: Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline

  8. Participant Satisfaction Assessed by a 5-Point Nominal Satisfaction Scale

    Participants will evaluate their satisfaction with the intervention using a nominal 5-point satisfaction scale ranging from much worse to much better than expected.

    Time frame: Baseline (Day 0), Day 12 (10th and final tDCS session), 3 months from baseline, and 6 months from baseline

  9. Program Adherence Measured Through the ReHub Platform

    Adherence to the exercise program will be monitored via the ReHub platform, recording the percentage of completed sessions over the total prescribed.

    Time frame: Throughout the 12-Week Exercise Program

07

Study locations

3 sites
08

References and documents

Publications

  • Linnhoff S, Haghikia A, Zaehle T. Effects of repetitive twice-weekly transcranial direct current stimulations on fatigue and fatigability in people with multiple sclerosis. Sci Rep. 2023 Apr 11;13(1):5878. doi: 10.1038/s41598-023-32779-y. PubMed 37041183 ↗
  • Mortezanejad M, Ehsani F, Masoudian N, Zoghi M, Jaberzadeh S. Comparing the effects of multi-session anodal trans-cranial direct current stimulation of primary motor and dorsolateral prefrontal cortices on fatigue and quality of life in patients with multiple sclerosis: a double-blind, randomized, sham-controlled trial. Clin Rehabil. 2020 Aug;34(8):1103-1111. doi: 10.1177/0269215520921506. Epub 2020 May 12. PubMed 32397748 ↗
  • Bertoli M, Tataranni A, Porziani S, Pasqualetti P, Gianni E, Grifoni J, L'Abbate T, Armonaite K, Conti L, Cancelli A, Cottone C, Marinozzi F, Bini F, Cecconi F, Tecchio F. Effects on Corticospinal Tract Homology of Faremus Personalized Neuromodulation Relieving Fatigue in Multiple Sclerosis: A Proof-of-Concept Study. Brain Sci. 2023 Mar 29;13(4):574. doi: 10.3390/brainsci13040574. PubMed 37190539 ↗
  • Xian C, Barbi C, Goldsworthy MR, Venturelli M, Sidhu SK. The interaction between metaplastic neuromodulation and fatigue in multiple sclerosis. J Neurol Sci. 2023 Jan 15;444:120521. doi: 10.1016/j.jns.2022.120521. Epub 2022 Dec 11. PubMed 36528976 ↗

Individual participant data

Plan to share: Yes — Age, sex, fatigue scoring, treatment, exercise adherence

Supporting information: Study protocol, Statistical analysis plan

Time frame: IPD and supporting information will be available beginning 6 months after publication of the primary results and will remain available for 5 years.

Access criteria: Qualified researchers with an approved proposal may request access to the de-identified IPD and supporting documents. Requests will be reviewed by the study sponsor. Data will be shared through a secure data access platform after signing a data use agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Feb 2027, 25 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 25 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Aug 2026 → Feb 2027 and completion Oct 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
May 5, 2026
StartActual
Jan 1, 2025
Primary completionEst.
Feb 28, 2027was Aug 2026
CompletionEst.
May 1, 2027was Oct 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Feb 28, 2027
Nov 18, 2026
Study completion
Oct 1, 2026→May 1, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Aug 31, 2026→Feb 28, 2027
    Study completion Oct 1, 2026→May 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07567989
Lead sponsor
Jacobo Formigo
Responsible party
Jacobo Formigo (Consultant in Physical and Rehabilitation Medicine and Head of the Interventional Rehabilitation Section, Fundación Pública Galega de Investigación Biomédica INIBIC) — Sponsor-investigator
First posted
May 5, 2026
Start date
Jan 1, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Jacobo Formigo, Dr,
study director · Complexo Hospitalario Universitario de A Coruña

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion